<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328692</url>
  </required_header>
  <id_info>
    <org_study_id>CKI-301</org_study_id>
    <secondary_id>2007_803</secondary_id>
    <secondary_id>MK7418-301</secondary_id>
    <nct_id>NCT00328692</nct_id>
  </id_info>
  <brief_title>PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaCardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NovaCardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to examine whether KW-3902IV will result in greater improvement&#xD;
      in signs and symptoms of heart failure, with less treatment failure than standard therapy,&#xD;
      when it is added to IV loop diuretics in subjects with acute heart failure syndrome and renal&#xD;
      impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Loop diuretics are generally first line therapy in patients hospitalized with acute heart&#xD;
      failure syndrome (AHFS). Their use far exceeds that of vasoactive agents. Tubuloglomerular&#xD;
      feedback (TGF) is the body's compensatory response to avoid excess fluid loss, and it is&#xD;
      activated when elevated sodium concentrations in the distal tubule are detected. TGF is&#xD;
      proposed as a contributing factor for the observed diuretic resistance that occurs in&#xD;
      patients with heart failure. Higher doses of diuretics are required to overcome the decreased&#xD;
      natriuresis and reduced RBF induced by TGF. Ultimately, this action creates a vicious cycle&#xD;
      of worsening renal function and diminished diuretic effectiveness.&#xD;
&#xD;
      The primary pharmacologic rationale for the use of KW-3902 in subjects with AHFS is its&#xD;
      mechanism of action as an adenosine A1 receptor antagonist. TGF promotes release of&#xD;
      adenosine, and adenosine binding to A1 receptors causes vasoconstriction of the afferent&#xD;
      arteriole, decreased RBF, and enhanced sodium reabsorption by the proximal tubule. This&#xD;
      action results in a decrease in GFR, diminished renal function, and sodium and water&#xD;
      retention. Blocking adenosine A1 receptors via a selective adenosine receptor antagonist may&#xD;
      limit sodium reabsorption by the proximal tubules without triggering TGF. It promotes&#xD;
      vasodilation of the afferent arteriole of the glomerulus, and thus, this strategy offers the&#xD;
      potential to overcome diuretic resistance or enhance diuretic responsiveness. It may also&#xD;
      reduce the need for increasing diuretic doses that have been associated with worse outcomes.&#xD;
&#xD;
      The objectives of this study are to evaluate the effect of KW-3902IV in addition to&#xD;
      intravenous (IV) loop diuretics (such as furosemide) on heart failure signs and symptoms,&#xD;
      renal function, and safety in subjects hospitalized with AHFS, volume overload, and renal&#xD;
      impairment, and to estimate and compare within-trial medical resource utilization and direct&#xD;
      medical costs between patients treated with KW-3902IV versus placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect on heart failure signs and symptoms</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>effect on renal function</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>within trial medical costs compared to placebo</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">932</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rolofylline</intervention_name>
    <description>rolofylline 30 mg IV QD; 3 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>KW-3902IV</other_name>
    <other_name>MK7418</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>rolofyline Pbo 30 mg IV QD; 3 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of heart failure of at least 14 days duration for which diuretic therapy has&#xD;
             been prescribed&#xD;
&#xD;
          2. Hospitalized for acute heart failure syndrome requiring IV diuretic therapy.&#xD;
&#xD;
          3. Impaired renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute contrast induced nephropathy&#xD;
&#xD;
          2. Ongoing or planned IV therapy for heart failure with positive inotropic agents,&#xD;
             vasopressors, vasodilators, or mechanical support with the exception of IV nitrates&#xD;
&#xD;
          3. BNP &lt;500pg/mL or NT-pro-BNP &lt;2000 pg/mL&#xD;
&#xD;
          4. Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis&#xD;
&#xD;
          5. Severe pulmonary disease&#xD;
&#xD;
          6. Significant stenotic valvular disease&#xD;
&#xD;
          7. Heart transplant recipient or admitted for cardiac transplantation&#xD;
&#xD;
          8. Clinical evidence of acute coronary syndrome in the 2 weeks prior to screening&#xD;
&#xD;
          9. Heart failure due to significant arrhythmias&#xD;
&#xD;
         10. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive&#xD;
             cardiomyopathy.&#xD;
&#xD;
         11. Known hepatic impairment&#xD;
&#xD;
         12. Non-cardiac pulmonary edema, including suspected sepsis&#xD;
&#xD;
         13. Allergy to soybean oil or eggs&#xD;
&#xD;
         14. History of seizure&#xD;
&#xD;
         15. Stroke within 2 years&#xD;
&#xD;
         16. History of or current brain tumor of any etiology&#xD;
&#xD;
         17. Brain surgery within 2 years&#xD;
&#xD;
         18. Encephalitis/meningitis within 2 years&#xD;
&#xD;
         19. History of penetrating head trauma&#xD;
&#xD;
         20. Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years&#xD;
&#xD;
         21. History of, or at risk for, alcohol withdrawal seizures&#xD;
&#xD;
         22. Advanced Alzheimer's disease&#xD;
&#xD;
         23. Advanced multiple sclerosis&#xD;
&#xD;
         24. Hgb &lt;8 g/dL, Hct &lt;25%, or the need for a blood transfusion&#xD;
&#xD;
         25. Previous exposure to KW-3902&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Massie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher O'Connor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Metra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Brescia, Italy</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>May 19, 2006</study_first_submitted>
  <study_first_submitted_qc>May 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2006</study_first_posted>
  <last_update_submitted>October 8, 2009</last_update_submitted>
  <last_update_submitted_qc>October 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>diuretic</keyword>
  <keyword>renal impairment</keyword>
  <keyword>renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rolofylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

